about
Glutathione S-transferase mu polymorphism does not explain variation in nitroglycerin responsivenessAdherence to MedicationPlasma antipyrine half-life can be determined from urine data.Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendationsRisk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults.Effect of temazepam on blood pressure regulation in healthy elderly subjects.Prazosin protein binding in health and disease.Disposition of ketoconazole, an oral antifungal, in humansProtein binding in antiretroviral therapies.Sex differences in pharmacokinetics and pharmacodynamics.Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes.Global challenges for clinical pharmacology in the developing world.Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories.Integrative continuum: accelerating therapeutic advances in rare autoimmune diseases.Introduction to the Theme "New Methods and Novel Therapeutic Approaches in Pharmacology and Toxicology".Discrepancies between pharmacokinetic studies of amitriptyline.Clinical pharmacokinetics of rifabutin.Primum non nocere? Valuing of the risk of drug toxicity in therapeutic decision making.Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide.Measurement of antipyrine half-life from urinary drug concentrations.Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.Effect of naloxone, a specific opioid inhibitor, on blood pressure fall during sleep.Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis.Responsiveness of superficial hand veins to adrenergic stimuli in patients with cystic fibrosis.Poor medication adherence in clinical trials: consequences and solutions.Introduction to the theme "Precision medicine and prediction in pharmacology".Introduction to the Theme "Cancer Pharmacology".Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics.Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.Increased vascular alpha1-adrenergic sensitivity in patients with renal failure: receiving recombinant erythropoeitin.Naloxone lowers plasma-prolactin in man.Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion Overview ChapterThe perils of public health by press releaseOptimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humansHeparin-induced vasodilation in human hand veins*Inhibition of angiotensin-converting enzyme in human hand veins
P50
Q23923528-5DF6A673-A3CB-43C6-8307-8586D4A312EAQ28314923-7A99D9ED-5E9E-40BC-9DFC-58CD1B5FD8FBQ30729599-25EB3258-7822-4E26-9F3F-E85D79782180Q31062643-FB6EA2E6-CFB7-466E-A21B-0379B39CE2D5Q33787619-937C9386-4F87-4288-ADA4-6F2656CA51D1Q34233363-432E5370-35E8-41A2-87B6-E4094BDEE469Q34398130-EEA3DC25-1AD1-4543-A131-5C5A1A41B631Q34518336-9E911E82-3E26-43B8-9229-16CE766BBA00Q34708257-15EEA75F-A930-4873-BD63-7474EE87882EQ35571186-1ABCA938-D9EC-41EF-A5EA-AE51089A8B6FQ35639177-81AFA696-A2C5-4609-93C7-6A78584B8E38Q37447871-6C18C168-2CDE-4CF7-9372-5769C265AAD5Q37487583-0C56141C-7477-4FAC-8E47-EC3E6C69241BQ37937669-298646B8-1190-474D-81E5-D07C753AE1FAQ37974925-C69FEA3D-A66D-4949-90C0-ADD373FCB6E9Q38978974-55243022-1214-45FD-9BDA-4CFC76DC463BQ39824454-07326251-B702-4ADF-94A7-0CC2DFABFEBFQ40517221-9BBCBEC5-4B68-4FC2-9505-F2376A34AE94Q40886873-31FD9944-E597-4D98-807B-6182C23E2396Q42268427-4168DD9D-8070-45AD-88D0-C04181BF4989Q42531541-F2359A4E-4B0D-4951-9D86-17B3D494EBADQ42671235-588AC45C-AB4E-4244-9385-48781EAF7263Q43890172-622E8C0A-D7FC-4CB4-8628-46D7AACBBCAAQ44217895-E635D6EB-E24E-49F6-B46F-1434ECD2644AQ44332357-F3E56E63-D98C-4764-AF41-686DA7810DFBQ44431076-45EA2C18-AC38-4E7E-99CF-355521A28210Q45364487-FE6A5906-0A8A-49C7-81A7-8604BFB8EC2CQ46110906-027945E3-F223-4539-B20B-AB497F79F0B3Q46228912-8203AF9E-E414-4309-A02F-22558129D040Q46324656-4B5AD733-17BB-4C32-83A8-83FBA46F20CEQ46511929-E1CFEE89-845C-413A-86C9-51ACB7CA88FAQ46614706-045BE815-0C80-46AC-8473-F4FC579A3C46Q46731853-4B312112-4249-4F98-98D5-D864606F97B9Q46985236-6ACFA482-A4BF-4B04-ACEF-168E181D2025Q51014384-9185FF9F-8341-4BC1-A9A4-35A89C3CC4BDQ58817106-BE424F3B-F073-4FA2-8BE7-748B5EAED078Q58817138-4DBC90CD-C135-471D-9570-AA957757A24CQ58817152-91156F6E-252E-4B48-9D4D-022D5BDF2B26Q58817160-93E673B2-E7C2-4417-A69E-DFA3E568896AQ58817168-018FA5B4-05F4-4A77-9AE7-DFF0EB893FFE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Terrence F. Blaschke
@ast
Terrence F. Blaschke
@en
Terrence F. Blaschke
@es
Terrence F. Blaschke
@nl
Terrence F. Blaschke
@sl
type
label
Terrence F. Blaschke
@ast
Terrence F. Blaschke
@en
Terrence F. Blaschke
@es
Terrence F. Blaschke
@nl
Terrence F. Blaschke
@sl
altLabel
Terry Blaschke
@en
prefLabel
Terrence F. Blaschke
@ast
Terrence F. Blaschke
@en
Terrence F. Blaschke
@es
Terrence F. Blaschke
@nl
Terrence F. Blaschke
@sl
P106
P1153
7005427513
P21
P31
P496
0000-0001-5307-2620